ArticleACS omega2019
Positron Emission Tomography Imaging of the Gastrin-Releasing Peptide Receptor with a Novel Bombesin Analogue.
Article in ACS omega, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Synthesis and Evaluation ofACS omega · 2026Article
- Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art.EJNMMI radiopharmacy and chemistry · 2026Review
- Studies on the impact of modifications at the Gln-Trp site in RM2-based GRPR ligands.EJNMMI research · 2025Article
- NovelPharmaceuticals (Basel, Switzerland) · 2025Article
- Synthesis and Evaluation of the FirstMolecules (Basel, Switzerland) · 2024Article
- Synthesis and Evaluation of NovelPharmaceuticals (Basel, Switzerland) · 2024Article
- Unnatural amino acid substitutions to improve in vivo stability and tumor uptake ofEJNMMI radiopharmacy and chemistry · 2024Article
- A prospective comparative study of [European journal of nuclear medicine and molecular imaging · 2023Article
- Synthesis and Preclinical Evaluation of NovelPharmaceuticals (Basel, Switzerland) · 2023Article
- Article
- Targeting the Gastrin-Releasing Peptide Receptor (GRP-R) in Cancer Therapy: Development of Bombesin-Based Peptide-Drug Conjugates.International journal of molecular sciences · 2023Article
- Synthesis and Preclinical Evaluation of Three NovelMolecules (Basel, Switzerland) · 2023Article
- Optimization of the Pharmacokinetic Profile of [Pharmaceuticals (Basel, Switzerland) · 2022Article
- Substitution of l-Tryptophan byJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Article
- Towards Complete Tumor Resection: Novel Dual-Modality Probes for Improved Image-Guided Surgery of GRPR-Expressing Prostate Cancer.Pharmaceutics · 2022Article
- Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.Theranostics · 2022Review
- Changes of Gastric Secretion after Bolus and Slow Intravenous Administration of Bombesin and Neurotensin.Maedica · 2021Article
- GMP-compliant production of [EJNMMI radiopharmacy and chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gastrin-releasing peptide receptor (GRPR), a G protein-coupled receptor, is overexpressed in solid malignancies and particularly in prostate cancer. We synthesized a novel bombesin derivative, [
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.